News

Corbus Pharmaceuticals announced that its CEO will give an update on clinical work and anticipated milestones for Resunab (JBT-101), the company’s synthetic oral drug designed to resolve chronic inflammation and fibrosis, at the upcoming Jefferies Cystic Fibrosis Summit. The treatment is under evaluation in three Phase 2 clinical trials. Last year, Corbus received…

Two studies published in the Journal of Clinical Investigation (JCI) demonstrate the potential of pigs with cystic fibrosis (CF) — the ExeGen CFTR miniswine model — to test the effectiveness and workings of gene therapies for the disease. This animal research model was developed by Exemplar Genetics, a subsidiary…

Corbus Pharmaceuticals Holdings recently announced the completion of patient enrollment in its Phase 2 clinical trial assessing Resunab for the treatment of cystic fibrosis (CF). Resunab is a first-in-class, synthetic oral endocannabinoid-mimetic drug that binds to the CB2 receptor present on activated immune cells and fibroblasts, helping resolve inflammation and halting…

A research team has developed a new way of specifically and efficiently identifying bacterial infections caused by the Burkholderia cepacia complex (BCC) in patients with cystic fibrosis (CF). This complex is among the most prevalent of bacterial infections detected in CF patients — who are known to be prone to chronic or recurrent lung…

According to the Cystic Fibrosis Foundation, because the severity and types of CF symptoms can vary from person to person, treatment therapies are individualized to suit each patient’s need. Every day, CF patients complete a combination of the following therapies: 1. Airway clearance This is necessary in order to…

A combination therapy with inhaled Bramitob (tobramycin) and Colistin improves lung function and respiratory symptoms in cystic fibrosis (CF) patients, according to a study published in the scientific journal Cellular Physiology and Biochemistry.

A new study published in the journal Science Advances sheds light on the molecular mechanisms responsible for the pathology of cystic fibrosis (CF), and may assist in the development of targeted therapies against the disease. Researchers investigated the role of two proteins, KCNE3 and KCNQ1, and how they can contribute…

Raptor Pharmaceuticals recently presented the results of a meta-analysis comparing the effectiveness of inhaled antibiotics for cystic fibrosis (CF) patients and Pseudomonas aeruginosa lung infections. The results, presented in London at the 2016 International Congress of the European Respiratory Society (ERS), showed that the company’s levofloxacin inhalation solution Quinsair was comparable in…

First Allied Securities hosted its annual national adviser conference this summer where 1,100 attendees participated not only in education, training, and networking, they also raised $72,000 for cystic fibrosis (CF) research through donations for the Cystic Fibrosis Foundation (CFF). An important part of the conference was the fundraising effort…

A new magnetic resonance imaging (MRI) technique, called ultrashort echo-time (UTE), can efficiently detect abnormalities in the structure and function of the lungs of patients with cystic fibrosis (CF), a study reports. This finding suggests that UTE-MRI can be an alternative to current ways of diagnosing CF, which expose patients to radiation. The…